AFG210

WARNING: This product is for research use only, not for human or veterinary use.

Description:AFG210 is a novel first-generation “type II” FLT3 inhibitor.

Price and Availability

AFG210, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406215Name: AFG210CAS#: 228400-22-4Chemical Formula: C19H14F3N3O2Exact Mass: 373.10381Molecular Weight: 373.33Elemental Analysis: C, 61.13; H, 3.78; F, 15.27; N, 11.26; O, 8.57

Synonym:AFG-210; AFG 210; AFG210.

IUPAC/Chemical Name:1-(4-(pyridin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

InChi Key:DDDLGNOZDKDSEG-UHFFFAOYSA-N

InChi Code:InChI=1S/C19H14F3N3O2/c20-19(21,22)13-2-1-3-15(12-13)25-18(26)24-14-4-6-16(7-5-14)27-17-8-10-23-11-9-17/h1-12H,(H2,24,25,26)

SMILES Code:O=C(NC1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(OC3=CC=NC=C3)C=C2

Technical Data

Additional Information

References

1: Weisberg E, Roesel J, Furet P, Bold G, Imbach P,Flörsheimer A, Caravatti G, Jiang J, Manley P, Ray A, Griffin JD.Antileukemic Effects of Novel First- and Second-Generation FLT3Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010Oct;1(10):1021-32. doi: 10.1177/1947601910396505. PubMed PMID: 21779428;PubMed Central PMCID: PMC3092267.